SCHEMBL14208653

SCHEMBL14208653

CO[C@H]1OC(COS(=O)(=O)O)[C@@H](O)[C@H](O[C@@H]2OC(C(=O)O)[C@@H](O)[C@H](O)C2O)C1NC(C)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BDNF P23560 3/20 0.65
PTN P21246 2/20 0.65
MDK P21741 2/20 0.65
F10 P00742 6/20 0.55
SERPINC1 P01008 1/20 0.44
FGF2 P09038 2/20 0.41
HPSE Q9Y251 2/20 0.41
LGALS3 P17931 4/20 0.40
LGALS1 P09382 1/20 0.39
LGALS7; LGALS7B P47929 1/20 0.39
BMP2 P12643 2/20 0.38
VEGFA P15692 2/20 0.38
CXCL12 P48061 2/20 0.38
SHH Q15465 2/20 0.38
IFNG P01579 1/20 0.38
PF4 P02776 1/20 0.38
CCL2 P13500 1/20 0.38
SELP P16109 1/20 0.38
BMP6 P22004 1/20 0.38
CCL11 P51671 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25785583 0.94 BDNF (0.62) BDNFPTNMDKF10SERPINC1
SCHEMBL27097990 0.93 BDNF (0.57) BDNFPTNMDKF10SERPINC1
SCHEMBL13321926 0.89 BDNF (0.61) BDNFPTNMDKF10SERPINC1
SCHEMBL13431406 0.88 BDNF (0.69) BDNFPTNMDKF10SERPINC1
SCHEMBL13321923 0.87 BDNF (0.54) BDNFPTNMDKF10SERPINC1
SCHEMBL14208664 0.85 F10 (0.51) BDNFPTNMDKF10SERPINC1
SCHEMBL13431418 0.85 BDNF (0.70) BDNFPTNMDKF10FGF2
SCHEMBL13431409 0.85 BDNF (0.70) BDNFPTNMDKF10FGF2
SCHEMBL13431469 0.85 BDNF (0.70) BDNFPTNMDKF10FGF2
SCHEMBL13321919 0.83 BDNF (0.47) BDNFPTNMDKF10HPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785416-B2 Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases BIOIBERICA, S.A. (ES) 2014-07-22 US disclosed
US-20120309707-A1 SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES UNIVERSIDAD AUTONOMA DE MADRID (ES) 2012-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309707-A1 SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES GALC, SMN1; SMN2, SORD BDNF 46/4885PTN 1620/4885MDK 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.